Short Interest in Redhill Biopharma Ltd. (NASDAQ:RDHL) Rises By 382.6%

Redhill Biopharma Ltd. (NASDAQ:RDHL) was the target of a large increase in short interest in January. As of January 15th, there was short interest totaling 175,260 shares, an increase of 382.6% from the December 31st total of 36,318 shares. Currently, 3.7% of the company’s stock are short sold. Based on an average trading volume of 2,480,934 shares, the days-to-cover ratio is presently 0.1 days. Based on an average trading volume of 2,480,934 shares, the days-to-cover ratio is presently 0.1 days. Currently, 3.7% of the company’s stock are short sold.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Redhill Biopharma in a research report on Thursday, January 22nd. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Redhill Biopharma has a consensus rating of “Sell”.

Institutional Investors Weigh In On Redhill Biopharma

A hedge fund recently bought a new stake in Redhill Biopharma stock. Gagnon Securities LLC acquired a new stake in Redhill Biopharma Ltd. (NASDAQ:RDHL) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 17,822 shares of the biotechnology company’s stock, valued at approximately $39,000. Gagnon Securities LLC owned 0.54% of Redhill Biopharma as of its most recent filing with the Securities and Exchange Commission. 7.20% of the stock is currently owned by institutional investors and hedge funds.

Redhill Biopharma Price Performance

Shares of RDHL stock traded down $0.02 during trading hours on Thursday, hitting $1.27. The stock had a trading volume of 41,746 shares, compared to its average volume of 1,432,687. The stock’s 50 day moving average is $1.20 and its 200 day moving average is $1.42. The firm has a market capitalization of $6.47 million, a PE ratio of 0.00 and a beta of 4.87. Redhill Biopharma has a twelve month low of $0.91 and a twelve month high of $6.26.

About Redhill Biopharma

RedHill Biopharma Ltd. is a specialty biopharmaceutical company focused on the development and commercialization of proprietary, orally-administered small molecules for the treatment of inflammatory, gastrointestinal and oncology indications. Founded in 2009 and headquartered in Tel Aviv, Israel, RedHill is publicly traded on the Nasdaq under the symbol RDHL. The company’s strategy centers on in-licensing late-stage clinical candidates and advancing them through regulatory review toward global commercialization.

RedHill’s lead marketed product, Talicia® (formerly RHB-105), is an FDA-approved, three-drug treatment for Helicobacter pylori infection, co-commercialized in the United States through a partnership with Bausch Health.